With the 
support of the U.S. Congress, the U.S. government, through the U.S. 
Agency for International Development’s (USAID’s) neglected tropical 
disease (NTD) Program, has supported countries to deliver more than half a billion NTD treatments in
 just six years, reaching cumulatively more than 250 million people in 
20 countries. Leveraging unprecedented donations of medicines by 
pharmaceutical companies, global neglected tropical disease (NTD) 
partnerships are supporting countries around the world to control and 
eliminate these diseases. 
  
  
The United
 States today is joining more than 40 nongovernmental organizations, 
academic institutions, global health and civil society organizations to 
hail historic progress, celebrate champions, and underscore continuing 
challenges in the global fight against diseases affecting the world’s 
poorest and most marginal populations. 
NTDs
 are caused by a range of worms, bacteria and parasites with 
hard-to-pronounce names such as schistosomiasis, lymphatic filariasis 
and onchocerciasis. They disproportionately impact poor and rural 
populations who lack access to safe water, adequate sanitation, and 
health care. These diseases can kill and frequently impair, blind, or 
disfigure those they infect. NTDs devastate families and communities by 
hindering children’s mental and physical development, reducing school 
performance and attendance, and limiting economic productivity in adults
 who become blind or too sick to work, thereby keeping families in a 
continuous cycle of poverty. Due to their primary role as caretakers of 
children, women are more commonly affected than men, suffering from NTDs
 like trachoma which causes pain and blindness during the most 
productive years of life. And certain NTDs, like Chagas disease and 
sleeping sickness, are potentially fatal without treatment.
“To
 date, USAID’s NTD program is the largest public-private partnership 
collaboration in our 50 year history,” states Dr. Ariel Pablos-Mendez, 
Assistant Administrator for USAID’s Global Health Bureau. “Over the past
 six years, USAID has leveraged over $3 billion in donated medicines 
reflecting one of the most cost effective public health programs. 
Because of this support, we are beginning to document control and 
elimination of these diseases in our focus countries and we are on track
 to meet the 2020 goals.”
Global 
partnerships have been instrumental to the efforts of governments and 
others who work together to create new medicines, get the drugs to the 
communities that need them, and enlist local support to ensure 
appropriateness of proposed interventions. Our work is making a 
large-scale, cost-effective contribution to the global effort to reduce 
the burden of NTDs.
All
 partners are committed to sustaining or expanding existing drug 
donation programs; accelerating research and development of new drugs, 
vaccines, and diagnostics; and strengthening drug distribution and 
implementation programs in disease-endemic countries. 
 
 
No comments:
Post a Comment